2022
Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis–Associated Interstitial Lung Disease
Yang MM, Balmert LC, Marangoni RG, Carns M, Hinchcliff M, Korman BD, Varga J. Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Care & Research 2022, 75: 152-157. PMID: 34251759, PMCID: PMC9233895, DOI: 10.1002/acr.24749.Peer-Reviewed Original ResearchMeSH KeywordsCross-Sectional StudiesHumansLongitudinal StudiesLungLung Diseases, InterstitialRetrospective StudiesScleroderma, SystemicVital CapacityConceptsC1q/tumor necrosis factor-related protein 9Interstitial lung diseaseSystemic sclerosisLung diseaseLung functionSystemic Sclerosis-Associated Interstitial Lung DiseaseSSc-associated interstitial lung diseasePulmonary function test dataLatent trajectory analysisVital capacity percentWorse lung functionPrimary outcome measureWorse pulmonary functionCause of morbidityRetrospective longitudinal studyAdipose tissue metabolismCross-sectional analysisAdipokine homeostasisDisease stabilityPulmonary functionSSc patientsSerum levelsPatient RegistryPredictive markerCapacity percent
2020
Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study
Thombs B, Kwakkenbos L, Henry R, Carrier M, Patten S, Harb S, Bourgeault A, Tao L, Bartlett S, Mouthon L, Varga J, Benedetti A, Advisors F, Fortuné C, Gietzen A, Guillot G, Lewis N, Richard M, Sauvé M, Welling J, Fligelstone K, Gottesman K, Leite C, Pérez E, Investigators S, Baron M, Malcarne V, Mayes M, Nielson W, Riggs R, Assassi S, Ells C, van den Ende C, Frech T, Harel D, Hinchcliff M, Hudson M, Johnson S, Larche M, Nguyen C, Pope J, Rannou F, Reyna T, Schouffoer A, Suarez-Almazor M, Agard C, Albert A, Bernstein E, Berthier S, Bissonnette L, Bruns A, Carreira P, Chaigne B, Chung L, Correia C, Denton C, Domsic R, Dunne J, Dunogue B, Farge-Bancel D, Fortin P, Gordon J, Granel-Rey B, Hatron P, Herrick A, Hoa S, Jones N, de B. Fernandes A, Kafaja S, Khalidi N, Launay D, Manning J, Marie I, Martin M, Mekinian A, Melchor S, Nikpour M, Olagne L, Proudman S, Régent A, Rivière S, Robinson D, Rodriguez E, Roux S, Sobanski V, Steen V, Sutton E, Thorne C, Wilcox P, Ayala M, Carboni-Jiménez A, Gagarine M, Nordlund J, Østbø N, Rice D, Turner K, Culos-Reed N, Dyas L, El-Baalbaki G, Hebblethwaite S, Bustamante L, Duchek D, Ellis K. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Journal Of Psychosomatic Research 2020, 139: 110262. PMID: 33070043, PMCID: PMC7532799, DOI: 10.1016/j.jpsychores.2020.110262.Peer-Reviewed Original Research
2018
Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin
Hinchcliff M, Toledo DM, Taroni JN, Wood TA, Franks JM, Ball MS, Hoffmann A, Amin SM, Tan AU, Tom K, Nesbeth Y, Lee J, Ma M, Aren K, Carns MA, Pioli PA, Whitfield ML. Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. Journal Of Investigative Dermatology 2018, 138: 1301-1310. PMID: 29391252, PMCID: PMC6590516, DOI: 10.1016/j.jid.2018.01.006.Peer-Reviewed Original ResearchConceptsMycophenolate mofetil treatmentMyeloid cell numbersMMF therapyMofetil treatmentSystemic sclerosisInflammatory scoreSkin biopsiesCell numberSkin myeloid cellsMyeloid dendritic cellsHalf of patientsRodnan skin scoreImmune cell numbersInflammatory gene signatureExpression of chemokinesProtein levelsCCL2 protein levelsCCL2 mRNA expressionInflammatory signatureDendritic cellsSkin scoreCCL2 mRNAEleven subjectsMonocyte migrationMyeloid cells
2014
Longitudinal Evaluation of PROMIS-29 and FACIT-Dyspnea Short Forms in Systemic Sclerosis
Hinchcliff ME, Beaumont JL, Carns MA, Podlusky S, Thavarajah K, Varga J, Cella D, Chang RW. Longitudinal Evaluation of PROMIS-29 and FACIT-Dyspnea Short Forms in Systemic Sclerosis. The Journal Of Rheumatology 2014, 42: 64-72. PMID: 25362656, PMCID: PMC4480645, DOI: 10.3899/jrheum.140143.Peer-Reviewed Original ResearchConceptsSystemic sclerosisPROMIS-29HAQ-DIHealth statusSF-36 physical component summaryShort formChange scoresSF-36 rolePhysical component scaleSF-36 scoresOutcomes Measurement Information SystemPhysical component summarySF-36 PCSPhysical function scalePhysical function assessmentMeasurement Information SystemMRSS improvementComponent summarySF-36Spearman correlation coefficientPhysical functionPhysical functioningHealth profileFunction assessmentFunctional limitationsDevelopment of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study
Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, Silver R, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Alkassab F, Steen VD. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Seminars In Arthritis And Rheumatism 2014, 44: 55-62. PMID: 24709277, DOI: 10.1016/j.semarthrit.2014.03.002.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedFemaleHumansHypertension, PulmonaryLongitudinal StudiesMaleMiddle AgedProspective StudiesRaynaud DiseaseRegistriesRiskScleroderma, SystemicConceptsSystolic pulmonary arterial pressureRight heart catheterizationExercise-induced hypoxiaPulmonary hypertensionPulmonary arterial hypertensionPulmonary function testingSystemic sclerosisCohort studyDisease durationHigher systolic pulmonary arterial pressureProspective longitudinal cohort studyFVC/DLcoNew pulmonary hypertensionPulmonary Hypertension AssessmentDiffusion lung capacityPulmonary arterial pressureOngoing prospective studyKaplan-Meier survivalHigh-risk populationKaplan-Meier estimatesLongitudinal cohort studyHigh-risk factorsRecognition of OutcomesPFT criteriaPH patientsSurvival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry
Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, Derk C, Fischer A, Frech T, Furst DE, Gomberg‐Maitland M, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TA, Molitor JA, Preston IR, Schiopu E, Shapiro L, Silver R, Simms R, Varga J, Gordon JK, Steen VD. Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care & Research 2014, 66: 489-495. PMID: 23983198, DOI: 10.1002/acr.22121.Peer-Reviewed Original ResearchConceptsPulmonary arterial hypertensionPulmonary Hypertension AssessmentCumulative survival rateRecognition of OutcomesSurvival rateScleroderma RegistryArterial hypertensionSSc patientsHypertension assessmentRoutine screeningWorld Health Organization group I PAHSystemic sclerosis associated pulmonary arterial hypertensionGroup I pulmonary arterial hypertensionSSc-associated pulmonary arterial hypertensionIncident pulmonary arterial hypertensionSSc centersRight-sided heart catheterizationDefinite pulmonary hypertensionIncident systemic sclerosisPredictors of mortalityMonths of enrollmentHeart catheterizationPAH diagnosisProspective registryPulmonary hypertension